Across TCGA pan-cancer cohorts, TNFRSF18 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TNFRSF18 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TNFRSF18 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TNFRSF18 expression acts as an unfavorable survival marker.

LUSC, LUAD, and PRAD are the cancer types where TNFRSF18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	36	view →
LUAD	OS	Median	II,III,IV	0.163	0.750	.001	24	view →
PRAD	DFS	Median	All	0.129	0.774	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TNFRSF18 tumor-vs-normal RNA expression · all TNFRSF18 data types